Laboratoires Euromedis Société anonyme (ALEMG) Fair Value & Analysis
Healthcare · FR · Market cap €15.1M
Fair value as of: Jun 24, 2026
Analysis
Laboratoires Euromedis Société anonyme (ALEMG) currently trades at €5.35, while our model-based Fair Value estimate is €5.32 — implying the stock looks roughly 0.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
About the company
Laboratoires Euromedis Société anonyme manufactures, imports, and distributes single-use medical devices for public and private healthcare facilities. It provides gloves; clothing and protection; draping and fields; compresses, cotton, dressings, strips and nets, and skincare products; sets and instrumentation; needles, syringes, microperfusionists; infusion and transfusion services, catheters, accessories, waste collectors; disinfection, hygiene, and surface protection; panty liners and sanitary napkins, changes, absorbent underwear, support briefs, and bed pad; rollators, cannes, and transfer products; bed tables, reclining chairs, and bath and toilet products; blood pressure monitors, thermometers, pulse oximeters, and other diagnostic products; urine bags, probes, and drains; and oxygen therapy products. The company was founded in 1985 and is based in Mouy, France.
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Laboratoires Euromedis Société anonyme (ALEMG) undervalued?
What is the fair value of ALEMG?
What is the quality score of ALEMG?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.